You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

IPSS-R intermediate risk

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

MDS, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic Trial in Newcastle (Subcutaneous azacitidine, Oral

Not yet recruiting
  • Myelodysplastic Syndromes
  • +3 more
  • Subcutaneous azacitidine
  • Oral decitabine/cedazuridine
  • Newcastle, New South Wales, Australia
    Calvary Mater Newcastle
May 29, 2023

MDS Trial in Worldwide (Oral Azacitidine, Placebo for Oral Azacitidine)

Not yet recruiting
  • Myelodysplastic Syndromes
  • Oral Azacitidine
  • Placebo for Oral Azacitidine
  • Buenos Aires, Argentina
  • +1 more
Aug 1, 2022

Anemia in MDS Trial in Plantation, Bronx, Austin (TP-0184)

Completed
  • Anemia in Myelodysplastic Syndromes
  • Plantation, Florida
  • +2 more
Apr 4, 2022

Very Low Risk, Low Risk, or Intermediate Risk MDS Per IPSS-R Trial in Canada, United States (Etavopivat)

Recruiting
  • Very Low Risk, Low Risk, or Intermediate Risk MDS Per IPSS-R
  • Ocala, Florida
  • +3 more
Jan 30, 2023

Anemia Trial (Luspatercept)

Not yet recruiting
  • Anemia
  • Luspatercept
  • (no location specified)
May 26, 2023

AML, MDS, Old Age; Debility Trial in Suzhou (Azacitidine, all trans retinoic acid)

Recruiting
  • AML
  • +3 more
  • Suzhou, Jiangsu, China
    The First Affiliated Hospital of Soochow University
Dec 27, 2021

MDS Trial in Worldwide (MBG453, Placebo, Hypomethylating agents)

Active, not recruiting
  • Myelodysplastic Syndromes
  • Duarte, California
  • +46 more
Jan 20, 2023

Anemia, MDS Trial in Germany (Canakinumab Injection)

Recruiting
  • Anemia
  • Myelodysplastic Syndromes
  • Canakinumab Injection
  • Berlin, Germany
  • +5 more
Nov 8, 2022

MDS Trial in China, Japan (Luspatercept)

Recruiting
  • Myelodysplastic Syndromes
  • Beijing, China
  • +33 more
Aug 16, 2022

Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, Recurrent Chronic Myelomonocytic Leukemia Trial in Houston

Recruiting
  • Chronic Myelomonocytic Leukemia
  • +5 more
  • Canakinumab
  • Houston, Texas
    M D Anderson Cancer Center
Dec 7, 2022

Myelodysplastic Syndrome (MDS) Trial in United States (MBG453, Azacitidine, Decitabine)

Recruiting
  • Myelodysplastic Syndrome (MDS)
  • Chandler, Arizona
  • +22 more
Dec 5, 2022

Prostate Cancer Trial in Roma (Soractelite Echolaser Transperineal focal laser ablation)

Recruiting
  • Prostate Cancer
  • Soractelite Echolaser Transperineal focal laser ablation
  • Roma, RM, Italy
    San Carlo di Nancy Hospital
Oct 16, 2022

Lower Risk MDS Per IPSS-R Trial (Luspatercept)

Not yet recruiting
  • Lower Risk MDS Per IPSS-R
  • (no location specified)
Jun 21, 2023

MDS Trial in Worldwide (Luspatercept, Epoetin Alfa)

Not yet recruiting
  • Myelodysplastic Syndromes
  • Luspatercept
  • Epoetin Alfa
  • Concord, California
  • +100 more
Jul 20, 2023

Azacitidine in International Prognostic Scoring System

Recruiting
  • Myelodysplastic Syndromes
  • +2 more
    • Hefei, Anhui, China
    • +16 more
    Sep 6, 2022

    MDS and Allogeneic Stem Cell Transplantation Trial in Perugia (MDS and AlloHSCT)

    Recruiting
    • MDS and Allogeneic Stem Cell Transplantation
    • MDS and AlloHSCT
    • Perugia, PG, Italy
      University of Perugia
    Mar 11, 2021

    MDS Trial in Worldwide (Luspatercept)

    Not yet recruiting
    • Myelodysplastic Syndromes
    • Los Alamitos, California
    • +53 more
    Sep 13, 2023

    High Risk Myelodysplastic Syndrome, IPSS Risk Category Intermediate-1, Myelodysplastic Syndrome Trial in Houston (Azacitidine,

    Active, not recruiting
    Has Results
    • High Risk Myelodysplastic Syndrome
    • +2 more
    • Houston, Texas
      M D Anderson Cancer Center
    Aug 11, 2022

    MDS Trial in Worldwide (Luspatercept, Placebo)

    Completed
    Has Results
    • Myelodysplastic Syndromes
    • Stanford, California
    • +73 more
    Nov 19, 2021

    Primary MDS (Very Low, Low or Intermediate IPSS-R With <5% Blasts) Trial in Worldwide (FG-4592, Placebo)

    Active, not recruiting
    • Primary MDS (Very Low, Low or Intermediate IPSS-R With <5% Blasts)
    • Los Angeles, California
    • +71 more
    Sep 16, 2022

    Acute Myeloid Leukemia With Multilineage Dysplasia, Blasts 20-30 Percent of Bone Marrow Nucleated Cells, Blasts 20-30 Percent of

    Active, not recruiting
    • Acute Myeloid Leukemia With Multilineage Dysplasia
    • +6 more
    • Houston, Texas
      M D Anderson Cancer Center
    Feb 25, 2022

    Brain and CNS Tumors Trial in Australia, United States (Induction Chemotherapy, Low-Risk Therapy, High-Risk Therapy)

    Active, not recruiting
    Has Results
    • Brain and Central Nervous System Tumors
    • Induction Chemotherapy
    • +3 more
    • Palo Alto, California
    • +5 more
    Nov 29, 2022

    MDS, CMML Trial in Florence (CC-486)

    Recruiting
    • MDS
    • CMML
    • Florence, Italy
      AOU Careggi- University of Florence
    Mar 16, 2021

    Myelodysplastic Syndrome (MDS) Trial in Worldwide (sabatolimab, azacitidine, venetoclax)

    Active, not recruiting
    • Myelodysplastic Syndrome (MDS)
    • Brasschaat, Belgium
    • +9 more
    Jan 19, 2023

    MDS Trial in France, Germany (N-Plate / romiplostim)

    Completed
    • Myelodysplastic Syndromes
    • N-Plate / romiplostim
    • Annecy, France
    • +35 more
    Sep 7, 2021